Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Scientific Rationale Supporting the Clinical Development Strategy for the Investigational Aurora A Kinase Inhibitor Alisertib in Cancer
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 5, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2015-08-24
DOI
10.3389/fonc.2015.00189
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Aurora kinase A and B as new treatment targets in aromatase inhibitor-resistant breast cancer cells
- (2015) Stine Hole et al. BREAST CANCER RESEARCH AND TREATMENT
- Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma
- (2015) K. M. Zullo et al. CLINICAL CANCER RESEARCH
- Prognostic value of Aurora kinase A (AURKA) expression among solid tumor patients: a systematic review and meta-analysis
- (2015) Jiao Zhang et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108
- (2015) Paul M. Barr et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 study
- (2015) Bohuslav Melichar et al. LANCET ONCOLOGY
- Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children
- (2015) Cynthia Wetmore et al. NEURO-ONCOLOGY
- Prostate Cancer and Neuroendocrine Differentiation: More Neuronal, Less Endocrine?
- (2015) Alexandru Dan Grigore et al. Frontiers in Oncology
- Aurora Kinase Inhibition Overcomes Cetuximab Resistance in Squamous Cell Cancer of the Head and Neck
- (2015) Alexander Hoellein et al. Oncotarget
- Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal TreatmentRelated Neuroendocrine Prostate Cancer
- (2015) Juan Miguel Mosquera et al. NEOPLASIA
- Drugging MYCN through an Allosteric Transition in Aurora Kinase A
- (2014) William Clay Gustafson et al. CANCER CELL
- Mdm2 and Aurora Kinase A Inhibitors Synergize to Block Melanoma Growth by Driving Apoptosis and Immune Clearance of Tumor Cells
- (2014) A. E. Vilgelm et al. CANCER RESEARCH
- Aurora-A Inhibition Offers a Novel Therapy Effective against Intracranial Glioblastoma
- (2014) J. R. Van Brocklyn et al. CANCER RESEARCH
- Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships
- (2014) Karthik Venkatakrishnan et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Aurora-A contributes to cisplatin resistance and lymphatic metastasis in non-small cell lung cancer and predicts poor prognosis
- (2014) Jie Xu et al. Journal of Translational Medicine
- Translational Exposure-Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib)
- (2014) J. J. Huck et al. MOLECULAR CANCER THERAPEUTICS
- Aurora-A Mitotic Kinase Induces Endocrine Resistance through Down-Regulation of ERα Expression in Initially ERα+ Breast Cancer Cells
- (2014) Mateusz Opyrchal et al. PLoS One
- Patient-derived models of acquired resistance can identify effective drug combinations for cancer
- (2014) Adam S. Crystal et al. SCIENCE
- Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma
- (2013) Markus Brockmann et al. CANCER CELL
- The Investigational Aurora Kinase A Inhibitor MLN8237 Induces Defects in Cell Viability and Cell-Cycle Progression in Malignant Bladder Cancer Cells In Vitro and In Vivo
- (2013) N. Zhou et al. CLINICAL CANCER RESEARCH
- Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2013) Kevin R. Kelly et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas
- (2013) Jonathan W. Friedberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Response to MLN8237 in Pancreatic Cancer Is Not Dependent on RalA Phosphorylation
- (2013) N. F. Neel et al. MOLECULAR CANCER THERAPEUTICS
- Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion
- (2013) T-V Do et al. ONCOGENE
- The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ERα+ breast cancer cells
- (2013) A B D'Assoro et al. ONCOGENE
- Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients
- (2012) Wulf Siggelkow et al. BMC CANCER
- The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas
- (2012) Vikas Sehdev et al. CANCER
- Pediatric Phase I Trial and Pharmacokinetic Study of MLN8237, an Investigational Oral Selective Small-Molecule Inhibitor of Aurora Kinase A: A Children's Oncology Group Phase I Consortium Study
- (2012) Y. P. Mosse et al. CLINICAL CANCER RESEARCH
- Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2012) A. Cervantes et al. CLINICAL CANCER RESEARCH
- Aurora A Inhibitor (MLN8237) plus Vincristine plus Rituximab Is Synthetic Lethal and a Potential Curative Therapy in Aggressive B-cell Non-Hodgkin Lymphoma
- (2012) D. Mahadevan et al. CLINICAL CANCER RESEARCH
- Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations
- (2012) E. C. Dees et al. CLINICAL CANCER RESEARCH
- Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
- (2012) Ursula A. Matulonis et al. GYNECOLOGIC ONCOLOGY
- Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines
- (2012) Jodi A. Muscal et al. INVESTIGATIONAL NEW DRUGS
- Targeting Aurora Kinase A enhances radiation sensitivity of atypical teratoid rhabdoid tumor cells
- (2012) Sujatha Venkataraman et al. JOURNAL OF NEURO-ONCOLOGY
- An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
- (2012) K. E. Hook et al. MOLECULAR CANCER THERAPEUTICS
- The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells
- (2012) V. Sehdev et al. MOLECULAR CANCER THERAPEUTICS
- Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
- (2012) Martin Peifer et al. NATURE GENETICS
- A framework for identification of actionable cancer genome dependencies in small cell lung cancer
- (2012) M. L. Sos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Aurora inhibitor MLN8237 in combination with docetaxel enhances apoptosis and anti-tumor activity in mantle cell lymphoma
- (2011) Wenqing Qi et al. BIOCHEMICAL PHARMACOLOGY
- Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer
- (2011) Hernan Carol et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Combining Histone Deacetylase Inhibitor Vorinostat with Aurora Kinase Inhibitors Enhances Lymphoma Cell Killing with Repression of c-Myc, hTERT, and microRNA Levels
- (2011) L. Kretzner et al. CANCER RESEARCH
- Aurora A Is a Repressed Effector Target of the Chromatin Remodeling Protein INI1/hSNF5 Required for Rhabdoid Tumor Cell Survival
- (2011) S. Lee et al. CANCER RESEARCH
- The inhibition of Aurora A abrogates the mitotic delay induced by microtubule perturbing agents
- (2011) Deborah R. Wysong et al. CELL CYCLE
- Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays
- (2011) M. G. Manfredi et al. CLINICAL CANCER RESEARCH
- The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo
- (2011) A. Faisal et al. MOLECULAR CANCER THERAPEUTICS
- Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets
- (2011) H. Beltran et al. Cancer Discovery
- Drug-Resistant Aurora A Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237
- (2010) Dominic A. Sloane et al. ACS Chemical Biology
- A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
- (2010) G. Gorgun et al. BLOOD
- Aurora A, Aurora B and survivin are novel targets of transcriptional regulation by histone deacetylase inhibitors in non-small cell lung cancer
- (2010) Xu-Hui Zhang et al. CANCER BIOLOGY & THERAPY
- The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
- (2010) Kevin R. Kelly et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- MK-5108, a Highly Selective Aurora-A Kinase Inhibitor, Shows Antitumor Activity Alone and in Combination with Docetaxel
- (2010) T. Shimomura et al. MOLECULAR CANCER THERAPEUTICS
- Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)
- (2010) John M. Maris et al. PEDIATRIC BLOOD & CANCER
- Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase
- (2010) D. Yang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies
- (2010) I. Astsaturov et al. Science Signaling
- Stabilization of N-Myc Is a Critical Function of Aurora A in Human Neuroblastoma
- (2009) Tobias Otto et al. CANCER CELL
- Dual Degradation of Aurora A and B Kinases by the Histone Deacetylase Inhibitor LBH589 Induces G2-M Arrest and Apoptosis of Renal Cancer Cells
- (2009) T.-L. Cha et al. CLINICAL CANCER RESEARCH
- Aurora-A Overexpression in Mouse Liver Causes p53-Dependent Premitotic Arrest during Liver Regeneration
- (2009) C.-C. Li et al. MOLECULAR CANCER RESEARCH
- Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice
- (2008) D Zhang et al. ONCOGENE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started